methylreboxetine
Small moleculeexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 10, 2017 (NCT03207464)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Norepinephrine transporterINHIBITOR
SC6A2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04403165 | N/A | Aug 6, 2020 | National Institute on Aging (NIA), New York University |
| NCT04144257 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2019 | Department of Defense, Harvard University |
| NCT03207464 | Phase 1/Phase 2 (Phase 2) | Oct 10, 2017 | Harvard University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Harvard University | Academic/Hospital | 2 | 2 | 1 | 2017 |
| Department of Defense | Government | 1 | 0 | 1 | 2019 |
| National Institute on Aging (NIA) | Government | 1 | 0 | 1 | 2020 |
| New York University | Academic/Hospital | 1 | 1 | 1 | 2020 |
4 organizations
Page 1 / 1